Show simple item record

dc.contributor.authorKatsanis, Emmanuel
dc.contributor.authorStea, Baldassarre
dc.contributor.authorKovacs, Kristen
dc.contributor.authorTruscott, Laurel
dc.contributor.authorHusnain, Muhammad
dc.contributor.authorKhurana, Sharad
dc.contributor.authorRoe, Denise J.
dc.contributor.authorSimpson, Richard J.
dc.identifier.citationKatsanis, E., Stea, B., Kovacs, K., Truscott, L., Husnain, M., Khurana, S., ... & Simpson, R. J. (2022). Feasibility and efficacy of partially replacing post-transplant cyclophosphamide with bendamustine in pediatric and young adult patients undergoing haploidentical bone marrow transplantation. Transplantation and Cellular Therapy.en_US
dc.description.abstractPost-transplantation cyclophosphamide (PT-CY) is the most widely applied graft-versus-host disease (GVHD) prophylaxis regimen in T cell-replete haploidentical bone marrow transplantation (haplo-BMT). Although PT-CY has met with great success in the haplo-BMT arena by suppressing GVHD, patients without acute GVHD have high relapse rates. One strategy to reduce relapse rates being explored by others is a dosage reduction of PT-CY. We have taken a different approach in evaluating whether partially replacing PT-CY with post-transplantation bendamustine (PT-BEN) would be advantageous, an idea based on our preclinical research identifying several beneficial immunomodulatory properties of BEN. We therefore initiated and completed a Phase Ia trial to evaluate the progressive substitution of PT-CY with PT-BEN ( identifier NCT02996773). We compared outcomes between 13 patients with high-risk hematologic malignancies who received PT-CY/BEN and 31 contemporaneous haplo-BMT recipients treated with the same myeloablative conditioning regimen but receiving only PT-CY. We found that partial replacement of PT-CY with PT-BEN (PT-CY/BEN) on day +4 was well tolerated and associated with significantly earlier trilineage engraftment. We also report favorable trends toward significant improvements on univariate and multivariate analyses with PT-CY/BEN compared with PT-CY with respect to rates of chronic GVHD (hazard ratio [HR], .08; 95% confidence interval [CI], .005 to 1.11; P = .06), and GVHD-free relapse-free survival (GRFS) (HR, .22; 95% CI, .05 to .86; P = .039). Our human trial has now transitioned to Phase Ib, which will further evaluate the safety and potential benefits of PT-CY/BEN. Herein we also expand our pediatric, adolescent, and young adult experience to 31 patients, demonstrating overall survival, progression-free survival, and GRFS at 3 years of 85.6%, 76.1%, and 58.2%, respectively, in a largely racial/ethnic minority cohort. PT-CY/BEN appears to be a promising treatment option that requires further evaluation.en_US
dc.publisherElsevier BVen_US
dc.rights© 2022 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy. This is an open access article under the CC BY-NC-ND license (
dc.titleFeasibility and Efficacy of Partially Replacing Post-Transplantation Cyclophosphamide with Bendamustine in Pediatric and Young Adult Patients Undergoing Haploidentical Bone Marrow Transplantationen_US
dc.contributor.departmentDepartment of Radiation Oncology, University of Arizonaen_US
dc.contributor.departmentUniversity of Arizona Cancer Centeren_US
dc.contributor.departmentDepartment of Epidemiology and Biostatistics, University of Arizonaen_US
dc.contributor.departmentDepartment of Pediatrics, University of Arizonaen_US
dc.contributor.departmentDepartment of Immunobiology, University of Arizonaen_US
dc.contributor.departmentSchool of Nutritional Sciences and Wellness, University of Arizonaen_US
dc.identifier.journalTransplantation and Cellular Therapyen_US
dc.description.noteOpen access articleen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleTransplantation and Cellular Therapy

Files in this item

Final Published Version

This item appears in the following Collection(s)

Show simple item record

© 2022 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy. This is an open access article under the CC BY-NC-ND license (
Except where otherwise noted, this item's license is described as © 2022 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy. This is an open access article under the CC BY-NC-ND license (